enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. UK Approves Merck's Hypertension Drug Acquired Via $11 ... - AOL

   www.aol.com/finance/uk-approves-mercks...

   After 24 weeks of treatment, sotatercept given in addition to other PAH medicines, improved the distance patients could walk in 6 minutes by around 34 meters, compared with 1 meter in patients who ...

3. Sotatercept - Wikipedia

   en.wikipedia.org/wiki/Sotatercept

   In the United States, sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1). [6] [10]In the European Union, sotatercept, in combination with other pulmonary arterial hypertension therapies, is indicated for the treatment of pulmonary arterial hypertension in adults with WHO Functional Class (FC) II to III, to improve exercise capacity.

4. Pulmonary arterial hypertension - Wikipedia

   en.wikipedia.org/.../Pulmonary_arterial_hypertension

   PAH is definitively diagnosed with a right heart catheterization showing a mean pulmonary arterial pressure greater than 20 mmHg at rest, with a pulmonary vascular resistance being 3 Woods Units or greater (indicative of pulmonary hypertension in the pre-capillary vasculature; the arteries and arterioles), and a pulmonary artery wedge pressure ...

5. Selexipag - Wikipedia

   en.wikipedia.org/wiki/Selexipag

   Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]

6. Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%

   www.aol.com/news/arena-arna-licenses-rights-pah...

   Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.

7. What You Need to Know About PAH Drugs in 2014 - AOL

   www.aol.com/2013/12/31/what-you-need-to-know...

   A host of newly approved drugs for pulmonary arterial hypertension, or PAH, means 2014 will be a battleground for market share in the multibillion-dollar indication. Among those competing will be ...